Hepatocellular Carcinoma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | AbbVie, H3 Biomedicine Inc., Bayer AG, Novartis, Pfizer.
| Published date | 16 April 2024 |
M2 PRESSWIRE-April 16, 2024-: Hepatocellular Carcinoma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | AbbVie, H3 Biomedicine Inc., Bayer AG, Novartis, Pfizer
(C)1994-2024 M2 COMMUNICATIONS
RDATE:16042024
The Hepatocellular Carcinoma Market Forecast report offers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma market trends in the 7MM.
DelveInsight's "Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast-2032'' report offers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hepatocellular Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatocellular Carcinoma Market Forecast
Some of the key facts of the Hepatocellular Carcinoma Market Report:
*The Hepatocellular Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032) *In March 2023, Ablaze Pharma unveiled its strategy to develop an innovative peptide drug, targeting GPC3, in Greater China. The peptide, known as RYZ801 and RYZ811, is proprietary and has been licensed from RayzeBio under an established agreement. *According to the Global Cancer Observatory, in the 7MM the ASR incident rate of liver cancer is 7.4/100,000 which is estimated to be around 135,533 new cases in 2020 *Nakano and colleagues (2022) conducted a study in Japan to analyze the epidemiological patterns of incident cases of Hepatocellular Carcinoma (HCC), focusing on factors such as gender, age, and disease causes. They examined data from 20,547 HCC patients between 1996 and 2019, dividing the study period into four 6-year intervals. HCC causes were classified as hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, HBV combined with HCV infection, and non-B and non-C etiologies. *According to the Global cancer observatory, in the Japan the ASR incident rate of liver cancer is 10.4/100,000 which is estimated to be around 45,663 new cases diagnosed in 2020 and the ASR mortality rate of liver cancer is 4.8/100,000 which is estimated to be around 28,155 number of deaths in 2020 *According to the Global cancer observatory in the United kingdom the ASR incident rate of liver cancer is 5.3/100,000 which is estimated to be around 8,156 new...
To continue reading
Request your trial